Gsa Capital Partners LLP Adaptimmune Therapeutics PLC Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

A detailed history of Gsa Capital Partners LLP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Gsa Capital Partners LLP holds 99,662 shares of ADAP stock, worth $59,797. This represents 0.01% of its overall portfolio holdings.

Number of Shares

99,662

Holding current value

$59,797

% of portfolio

0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$0.92 - $1.39 $91,689 - $138,530	99,662 New	99,662 $95,000
Q1 2024 May 03, 2024	SELL	$0.7 - $1.75 $97,040 - $242,600	-138,629 Reduced 27.25%	370,179 $584,000
Q4 2023 Feb 16, 2024	BUY	$0.43 - $0.79 $218,787 - $401,958	508,808 New	508,808 $401,000
Q2 2023 Aug 14, 2023	SELL	$0.9 - $1.51 $12,897 - $21,638	-14,330 Reduced 29.46%	34,307 $31,000
Q1 2023 May 12, 2023	SELL	$1.06 - $2.16 $97,993 - $199,685	-92,447 Reduced 65.53%	48,637 $53,000
Q4 2022 Feb 13, 2023	SELL	$1.05 - $2.53 $251,956 - $607,096	-239,959 Reduced 62.97%	141,084 $206,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.41 $403,905 - $918,313	381,043 New	381,043 $410,000
Q2 2022 Aug 09, 2022	SELL	$1.33 - $2.28 $92,583 - $158,715	-69,612 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.73 - $4.06 $25,114 - $58,939	-14,517 Reduced 17.26%	69,612 $143,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $1.4 Million - $2.28 Million	-400,653 Reduced 82.65%	84,129 $315,000
Q3 2021 Nov 12, 2021	SELL	$3.44 - $6.37 $98,404 - $182,220	-28,606 Reduced 5.57%	484,782 $2.51 Million
Q2 2021 Aug 05, 2021	BUY	$3.86 - $5.78 $1.62 Million - $2.43 Million	420,276 Added 451.37%	513,388 $2.19 Million
Q1 2021 May 10, 2021	SELL	$4.9 - $6.83 $1.13 Million - $1.57 Million	-229,632 Reduced 71.15%	93,112 $494,000
Q4 2020 Feb 03, 2021	BUY	$4.0 - $9.2 $995,188 - $2.29 Million	248,797 Added 336.45%	322,744 $1.74 Million
Q3 2020 Nov 06, 2020	BUY	$7.66 - $10.78 $566,434 - $797,148	73,947 New	73,947 $590,000
Q2 2020 Aug 11, 2020	SELL	$2.58 - $12.1 $49,585 - $232,549	-19,219 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$1.2 - $4.52 $100,410 - $378,210	-83,675 Reduced 81.32%	19,219 $52,000
Q4 2019 Feb 12, 2020	BUY	$0.72 - $1.43 $23,896 - $47,460	33,189 Added 47.61%	102,894 $123,000
Q3 2019 Nov 12, 2019	BUY	$1.43 - $3.81 $17,245 - $45,948	12,060 Added 20.92%	69,705 $105,000
Q2 2019 Aug 06, 2019	SELL	$3.23 - $5.41 $37,028 - $62,020	-11,464 Reduced 16.59%	57,645 $232,000
Q1 2019 May 15, 2019	BUY	$3.63 - $6.06 $250,865 - $418,800	69,109 New	69,109 $297,000
Q2 2018 Aug 09, 2018	SELL	$10.42 - $13.74 $791,003 - $1.04 Million	-75,912 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$7.1 - $11.56 $538,975 - $877,542	75,912 New	75,912 $852,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Adaptimmune Therapeutics PLC Transaction History